Shares of Aemetis, Inc (NASDAQ:AMTX) have received a consensus broker rating score of 3.00 (Hold) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a hold rating.
Brokers have set a 12 month consensus price target of $2.00 for the company and are predicting that the company will post ($0.24) EPS for the current quarter, according to Zacks. Zacks has also given Aemetis an industry rank of 238 out of 265 based on the ratings given to its competitors.
Several equities research analysts have issued reports on AMTX shares. Zacks Investment Research upgraded shares of Aemetis from a “sell” rating to a “hold” rating in a research report on Thursday. FBR & Co set a $2.00 price objective on shares of Aemetis and gave the stock a “hold” rating in a report on Tuesday, May 16th.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://stocknewstimes.com/2017/08/02/analysts-anticipate-aemetis-inc-amtx-to-post-0-24-earnings-per-share-updated.html.
An institutional investor recently raised its position in Aemetis stock. Geneva Advisors LLC raised its position in Aemetis, Inc (NASDAQ:AMTX) by 2.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,511,631 shares of the specialty chemicals company’s stock after buying an additional 32,400 shares during the period. Geneva Advisors LLC owned about 7.67% of Aemetis worth $1,950,000 at the end of the most recent quarter. Institutional investors and hedge funds own 19.02% of the company’s stock.
Shares of Aemetis (AMTX) traded up 0.82% during trading on Monday, reaching $1.23. 39,176 shares of the company’s stock traded hands. The company’s 50-day moving average is $1.39 and its 200 day moving average is $1.35. Aemetis has a 52-week low of $1.01 and a 52-week high of $2.50. The company’s market cap is $24.23 million.
Aemetis Company Profile
Aemetis, Inc is an international renewable fuels and biochemicals company. The Company is focused on the production of fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products by conversion of first-generation ethanol and biodiesel plants into biorefineries.
Get a free copy of the Zacks research report on Aemetis (AMTX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aemetis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aemetis Inc and related companies with MarketBeat.com's FREE daily email newsletter.
